A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others
TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…
GSK Enters Agreement to Acquire IDRx, Inc.
Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed…
